Marica Arvigo

Predictors of in vitro response to somatostatin and dopamine receptor‐targeted treatments are lacking in clinically non‐functioning pituitary tumors

Abstract Clinically non‐functioning pituitary neuroendocrine tumors (NF‐PitNETs) lack effective medical therapies, and the role of somatostatin receptor ligands (SRLs) and dopamine agonists (DAs) in this setting is controversial. We evaluated the in vitro response of NF‐PitNETs t...